Watch the 2021 Lecture by Dr. Jeffrey McClean II entitled “Organizational Equity, Diversity, and Inclusion: Driving Forces and Stumbling Blocks”
Annual Norman R. Seay Lecture (Links to an external site)
Author: Ronald
State of the Knight ADRC Lecture (Links to an external site)
View Dr. John C. Morris give the annual State of the Knight ADRC Lecture for 2021.
New Alzheimer’s treatment targets identified (Links to an external site)
A research team at Washington University School of Medicine in St. Louis has identified potential new treatment targets for Alzheimer’s disease, as well as existing drugs that have therapeutic potential against these targets.
We May Be Getting Closer to an Alzheimer’s Vaccine (Links to an external site)
A new study shows safety and potential benefit for patients with mild disease. Axon’s experimental vaccine AADVac1—currently the most clinically advanced tau therapy in development—aims to do exactly that. Its goal is to activate our bodies’ defense system to clear out free-floating tau proteins in our brains before they can form harmful tangles that accumulate inside nerve […]
Blood tests could help screen anticipated flood of patients seeking new Alzheimer’s drug (Links to an external site)
When the U.S. government approved the Alzheimer’s disease drug aducanumab last month despite shaky evidence of clinical benefits, Suzanne Schindler saw an immediate consequence: “We’re going to have to do a lot more biomarker testing.” Schindler, a neurologist at the Washington University School of Medicine in St. Louis, expects many patients with memory problems will […]
Investigational Alzheimer’s drug improves biomarkers of the disease (Links to an external site)
An investigational Alzheimer’s drug reduced molecular markers of disease and curbed neurodegeneration in the brain, without demonstrating evidence of cognitive benefit, in a phase 2/3 clinical trial led by researchers at Washington University School of Medicine in St. Louis through its Dominantly Inherited Alzheimer Network-Trials Unit (DIAN-TU). These results led the trial leaders to offer the drug, […]